<DOC>
	<DOCNO>NCT00614042</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability TRU-016 patient previously treat chronic lymphocytic leukemia , obtain estimate clinical activity patient CLL non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Phase 1/1b Study TRU-016 Patients With Previously Treated CLL Select Subtypes Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This Phase 1/1b open-label study consist two part . The initial portion Phase 1 dose-escalation study evaluate safety tolerability TRU-016 administer 4-week period patient relapse chronic lymphocytic leukemia ( CLL ) . It identify MTD evaluate pharmacokinetics immunogenicity TRU-016 . Upon demonstrate satisfactory safety tolerability Phase 1 portion , Phase 1b expansion cohort enrol characterize safety select dose first stage study safety estimate clinical activity TRU-016 patient treatment-naive CLL , relapse CLL non-Hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Diagnosis chronic lymphocytic lymphoma small lymphocytic lymphoma ( Phase 1 ) relapsed/refractory NHL ( Phase 1b ) Previous treatment least one fludarabinecontaining regimen Demonstrate least one follow criterion active disease require treatment : ) progressive splenomegaly and/or lymphadenopathy ; b ) anemia thrombocytopenia due bone marrow involvement ; c ) unintentional weight loss &gt; 10 % precede 6month period ; ) NCI Grade 2 3 fatigue ; e ) fever &gt; 100.5 F night sweat &gt; 2 week without infection ; f ) progressive lymphocytosis increase &gt; 50 % 2month period anticipate doubling time &lt; 6 month . ECOG performance status &lt; /= 2 SGOT , SGPT &lt; /= 2.0 x upper limit normal ANC &gt; /= 500/uL Platelets &gt; /= 30,000/uL Discontinued previous anticancer investigational therapy least 30 day Treatment rituximab within 30 day alemtuzumab ( Campath ) radioimmune therapy within 12 week ANC &lt; /= 500/uL Platelets &lt; /= 30,000/mm3 Previous concurrent additional malignancy Significant concurrent medical disease condition Hepatitis B surface antigen hepatitis B core antibody positive Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>TRU-016</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>